Cadrenal Therapeutics, INC Form 4 insider transactions

Quang Pham, Chairman and CEO of Cadrenal Therapeutics, Inc., reported the sale of 7,400 shares of common stock under a Rule 10b5-1 trading plan.

Quang Pham, Director and Officer of Cadrenal Therapeutics, reports sale of common stock under a Rule 10b5-1 trading plan.

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of common stock totaling 11,444 shares on June 22-23, 2026, under a Rule 10b5-1 trading plan.

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of 3,613 shares of common stock on June 16, 2026, and 513 shares on June 17, 2026, under a Rule 10b5-1 trading plan.

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 18,124 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 22,385 shares of common stock across three days in June 2026.

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 8,285 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics CEO Quang Pham sold a total of 652 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Cadrenal Therapeutics CEO and Chairman Quang Pham disclosed the sale of 12,763 shares of common stock executed under a pre-arranged Rule 10b5-1 trading plan.

Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc., reported the sale of 1,165 shares of common stock under a Rule 10b5-1 trading plan.

Cadrenal Therapeutics' Chief Financial Officer, Matthew K. Szot, sold all 9,933 directly owned shares of common stock for a weighted average price of $6.97 per share under a pre-arranged 10b5-1 trading plan.

Cadrenal Therapeutics, Inc. director Lee Scott Golden was granted 5,000 stock options with an exercise price of $8.27, vesting over time.

Cadrenal Therapeutics' CFO, Matthew K. Szot, sold 3,600 shares of common stock for $13.99 per share through a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 2,444 shares of common stock in late October 2025 under a pre-arranged trading plan.

Cadrenal Therapeutics' CFO, Matthew K. Szot, reported the sale of common stock totaling 3,493 shares through a pre-arranged 10b5-1 trading plan.

Cadrenal Therapeutics CEO and Chairman Quang X. Pham sold 3,600 shares of common stock in two transactions under a Rule 10b5-1 trading arrangement.

Cadrenal Therapeutics' Chief Financial Officer, Matthew K. Szot, sold 107 shares of common stock for $13.99 per share under a pre-arranged 10b5-1 trading plan.

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 500 shares of common stock under a Rule 10b5-1 trading plan.

Cadrenal Therapeutics' CFO, Matthew K. Szot, sold a total of 1,800 shares of common stock in late September and early October 2025 under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics CEO and Chairman Quang Pham reported the sale of 1,300 shares of common stock through pre-arranged Rule 10b5-1 trading plans.

Cadrenal Therapeutics CFO Matthew K. Szot sold a total of 12,400 shares of common stock in two separate transactions in late September 2025 under a pre-arranged trading plan.

Cadrenal Therapeutics CEO and Chairman, Quang X. Pham, reported the sale of 9,371 shares of common stock in late September 2025 under a pre-arranged trading plan.

Cadrenal Therapeutics' Chief Financial Officer, Matthew K. Szot, reported the sale of 2,000 common shares in pre-scheduled transactions.

Cadrenal Therapeutics' CEO and Chairman, Quang Pham, reported the sale of 5,029 shares of common stock in pre-scheduled transactions.

Quang X. Pham, CEO of Cadrenal Therapeutics, files an amendment to a previous Form 4 to correct the exercise price and expiration date of stock options granted.

James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc., reports the acquisition of stock options.

A director of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025.

Director Glynn Wilson of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025, which vest monthly over 12 months starting February 1, 2025.

A director of Cadrenal Therapeutics, Steven Zelenkofske, has acquired 20,000 stock options, vesting monthly over 12 months starting February 1, 2025.

Cadrenal Therapeutics' Chief Operating Officer, Jeffrey Scott Cole, was granted 25,000 stock options on January 23, 2025.